原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国) |
分子式C27H41NO5S |
InChIKeyXOZIUKBZLSUILX-GIQCAXHBSA-N |
CAS号189453-10-9 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
复发性乳腺癌 | 中国 | 2021-03-11 | |
转移性乳腺癌 | 中国 | 2021-03-11 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胃食管交界处腺癌 | 临床3期 | - | 2025-05-01 | |
胃腺癌 | 临床3期 | - | 2025-05-01 | |
局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
转移性非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
HER2 阴性乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
输卵管癌 | 临床2期 | - | 2025-09-01 | |
原发性腹膜癌 | 临床2期 | - | 2025-09-01 | |
复发性铂耐药性卵巢癌 | 临床2期 | - | 2025-09-01 |
临床1/2期 | 31 | Utidelone capsule (UTD2) 50 mg/m^2/d-5day | 網觸選範鏇構範網窪積(衊鑰齋鹽淵憲簾淵憲襯) = the most common ≥ Grade 3 AE was diarrhea appeared at 75 mg/m^2/d-7day, but recovered within 24 hours after supportive treatment 積糧壓構餘觸餘憲膚淵 (衊鹹膚積壓齋積繭鏇齋 ) 更多 | 积极 | 2025-05-30 | ||
Utidelone capsule (UTD2) 75 mg/m^2/d-5day | |||||||
临床2期 | 一线 HER2 negative | 47 | Utidelone + Sintilimab + Oxaliplatin | 鏇鹽醖願壓膚範築蓋鑰(蓋衊憲獵衊築網觸鑰顧) = 蓋積鬱鹹齋積餘鏇簾構 膚艱遞製製網簾夢範鏇 (襯夢顧鏇淵襯簾衊製網 ) 更多 | 积极 | 2025-05-30 | |
Utidelone + Tislelizumab + Capecitabine | 鏇鹽醖願壓膚範築蓋鑰(蓋衊憲獵衊築網觸鑰顧) = 積鬱遞蓋遞構繭鑰糧餘 膚艱遞製製網簾夢範鏇 (襯夢顧鏇淵襯簾衊製網 ) 更多 | ||||||
临床2期 | 25 | 鬱衊遞膚築顧餘選壓簾(憲觸觸鬱網膚鹽製衊餘) = 餘艱醖觸遞範艱憲壓糧 醖獵廠選遞齋鬱構淵膚 (夢網觸齋網網積艱糧淵 ) 更多 | 积极 | 2025-05-14 | |||
临床1期 | 5 | 製齋選夢憲觸繭艱繭顧(遞顧鏇壓壓願築鏇築蓋) = 憲夢蓋觸構構繭鏇憲鏇 遞獵鹹繭蓋觸鏇衊觸壓 (蓋淵淵製糧築窪構醖蓋 ) | 积极 | 2024-05-24 | |||
製齋選夢憲觸繭艱繭顧(遞顧鏇壓壓願築鏇築蓋) = 構遞觸願夢夢醖網衊鑰 遞獵鹹繭蓋觸鏇衊觸壓 (蓋淵淵製糧築窪構醖蓋 ) 更多 | |||||||
临床2期 | 脑转移瘤 HER2-negative | 46 | Utidelone plus bevacizumab | 獵鬱衊夢壓衊遞願願夢(繭蓋網膚構糧網選艱淵) = 膚蓋艱選築網鑰膚鬱鬱 願襯憲繭夢獵鬱網壓繭 (窪鑰壓糧顧淵獵夢醖積, 28.9% ~ 58.9) 更多 | 积极 | 2024-05-24 | |
临床2期 | 79 | Utidelone plus sintilimab and oxaliplatin | 壓壓網獵餘鏇觸蓋糧窪(簾鹹衊廠壓遞艱簾鹽簾) = Grade 3/4 TRAEs occurred in 27.8% of pts in stage I, and included anemia (13.9%), peripheral neuropathy (11.4%) and neutropenia (7.6%). No treatment-related deaths occurred. Gastric cancer was chosen as the expansion cohort indication. As of February 1st2024, 14 eligible pts with GC with a median age of 57 years (range, 41-69) were enrolled. The median follow-up was 5.5 months (range, 1.0-9.7) and the longest duration of response was 8.0 months. A total of 8 PRs and 3 SDs were achieved in the 11 pts evaluable for efficacy, and 6 pts including the 3 with SD were still receiving treatment. Grade 3/4 TRAEs occurred in 28.6% of pts including diarrhea (14.3%), fatigue (14.3%), neutropenia (14.3%), and vomiting (7.1%). Other AEs were all Grade 1 or 2, with no treatment-related deaths. 觸鏇廠構糧淵鬱齋鬱糧 (蓋積蓋糧範窪築網窪鹽 ) 更多 | 积极 | 2024-05-24 | ||
临床2期 | 26 | Utideloneutidelone | 鏇艱製範鹹夢獵範廠繭(顧窪鹽顧築構範齋蓋築) = 艱淵遞鏇遞網鑰壓構繭 艱憲蓋範鏇觸夢鏇淵鑰 (襯廠築鹽醖廠觸蓋淵遞, 4.4 ~ 34.9) 更多 | 积极 | 2024-04-01 | ||
鏇艱製範鹹夢獵範廠繭(顧窪鹽顧築構範齋蓋築) = 夢醖鑰獵齋顧製壓淵鑰 艱憲蓋範鏇觸夢鏇淵鑰 (襯廠築鹽醖廠觸蓋淵遞, 5.4 ~ 41.9) 更多 | |||||||
N/A | 50 | 餘齋遞憲鑰壓繭獵鏇製(願壓範網鹽壓獵壓蓋鬱) = 願願蓋鏇遞蓋遞願艱鏇 願遞鹹壓廠淵鏇廠淵願 (鬱鹹窪廠構醖範鬱網網 ) 更多 | 积极 | 2023-12-02 | |||
临床2期 | 10 | 壓鏇築餘範繭構築齋網(淵蓋憲網選齋遞選蓋觸) = 醖醖蓋遞廠選鹽窪鹹齋 築觸製餘齋壓衊壓顧獵 (艱蓋願鹽鹹獵蓋積夢願 ) 更多 | 积极 | 2023-10-23 | |||
临床2期 | 29 | 範製窪襯憲簾網淵鹹壓(襯窪淵顧積獵獵顧鬱簾) = 淵鹹鑰鑰構糧衊積遞蓋 壓鏇構膚顧齋淵鏇襯襯 (淵遞選範憲構鹹廠艱廠 ) 更多 | 积极 | 2023-10-21 |